View Exam | PowerPak

1. Which of the following characteristics defines a high-risk group of patients with R/R FL that need better treatments due to poorer outcomes?

A. Those with toxicity concerns B. Those with increased bulk of disease C. Patients with comorbidities D. Patients experiencing early relapse

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

A. DNA methyltransferase B. Histone acetyltransferase C. Histone methyltransferase D. Isocitrate dehydrogenase

3. Histone deacetylase inhibitors act to promote which of the following conditions in the epigenetic pathway?

A. A closed chromatin state B. An intermediate chromatin state C. An open chromatin state D. No chromatin state effect

4. Findings from a phase 2, open-label, multicenter study by Morshhauser et al, which evaluated the use of tazemetostat in patients with R/R FL and on which the FDA based its approval, demonstrated that:

A. A high frequency of grade 3 or higher treatment-related adverse events was associated with tazemetostat B. A reduction in response to tazemetostat was seen with continued treatment over time C. A significant tumor reduction was seen in patients with mutant and wild-type EZH2 receiving tazemetostat D. At least prior 3 systemic therapies had to be tried for therapeutic success

5. A 69-year-old woman was diagnosed with FL 4 years ago after a several-year history of painless inguinal adenopathy that was evaluated after noting an acute onset of lower back pain. After experiencing a recurrence 3 years ago and receiving a second line of systemic therapy, she remained in remission until 1 year ago when she was noted to have another recurrence and revealed to have an EZH2 mutation. Which of the following epigenetic-targeted treatments would be most appropriate for this patient in the third-line setting based on her profile and clinical characteristics?

A. Abexinostat B. Umbralisib C. Obinutuzumab D. Tazemetostat

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following characteristics defines a high-risk group of patients with R/R FL that need better treatments due to poorer outcomes?

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

3. Histone deacetylase inhibitors act to promote which of the following conditions in the epigenetic pathway?

4. Findings from a phase 2, open-label, multicenter study by Morshhauser et al, which evaluated the use of tazemetostat in patients with R/R FL and on which the FDA based its approval, demonstrated that:

« Return to Activity

Scheduled Maintenance to Improve Performance & Reliability

10/17/2024 4:00 PM EST - 10/17/2024 11:59 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following characteristics defines a high-risk group of patients with R/R FL that need better treatments due to poorer outcomes?

2. Enhancer of zeste homolog 2 (EZH2)-targeted therapies act to affect which part of the epigenetic pathway to promote an open chromatin state?

3. Histone deacetylase inhibitors act to promote which of the following conditions in the epigenetic pathway?

4. Findings from a phase 2, open-label, multicenter study by Morshhauser et al, which evaluated the use of tazemetostat in patients with R/R FL and on which the FDA based its approval, demonstrated that:

« Return to Activity

Customers who Purchased
this Activity also Purchased